Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib for second or third treatment-free remission attempt in chronic myeloid leukemia
2024-519472-69-00Phase 2Completed
- Sponsor
- Heidelberg University
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Heidelberg University. Primary endpoints: Molecular relapse-free survival at 12 months and Molecular relapse-free survival at 36 months. Started Nov 2024; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-519472-69-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519472-69-00.